Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Telangiectasia

Also known as: telangiectases, thread veins, broken capillaries

Telangiectasia is visible widening of small blood vessels near the surface of the skin or a mucous membrane. It can appear as fine red lines or a branching pattern, occur by itself, or accompany a skin or systemic condition.

In plain English — Telangiectasia means small surface blood vessels have become visibly widened. Some can be left alone, while selected facial vessels may be reduced with vascular laser or intense pulsed light. Repeated nosebleeds, vessels inside the mouth or other unexplained symptoms are reasons to seek medical assessment before cosmetic treatment.

Evidence status

Moderate

Established clinical finding; treatment evidence varies by presentation. Clinical references describe several causes and recognised treatment options. Randomised studies support selected vascular devices for facial vessels, while comparative certainty and long-term outcomes remain limited by small, heterogeneous studies.

What telangiectasia is, and the patterns encountered#

Telangiectasia is a visible vascular finding. Fine linear or branching red vessels may be localised or more widespread. Blue superficial vessels may instead represent dilated venules, sometimes called venulectasia. Documenting the appearance and distribution helps establish what is being assessed.[1]

A spider telangiectasis has a central red point with vessels radiating outward. Its central arteriole supplies the visible branches; clinical examination may show emptying under central pressure and refilling after release.[2]

Facial vessels may occur with rosacea or sun damage. Other contexts include familial patterns, previous injury, medicines and systemic disease. Long-term corticosteroid exposure and some vasodilator medicines are relevant history items.[1]

Use of telangiectasia assessment in aesthetic practice#

The practical role is to recognise the vascular pattern, understand the person’s concern and decide whether observation, supportive care, a vascular procedure or medical assessment is appropriate. A stable, recognised spider telangiectasis can be left alone when it is not troublesome.[2]

Where rosacea is present, vessel treatment sits within its wider care. Tolerated cleansing and moisturising, sun protection and attention to individual aggravating factors can support comfort and management. The rosacea entry covers that condition; the IPL guide explains the procedure.[3]

Contraindications and cautions#

An uncertain diagnosis requires assessment before treatment. Vessels can be a feature of other lesions, including basal cell carcinoma. A vascular-looking spot should not be destroyed simply because it is red.[1, 8]i

Unexplained recurrent bleeding or a pattern suggesting systemic disease changes the pathway to medical assessment, as set out under referral below.[7, 9]i[1, 6]i

For a proposed device procedure, lesion site, skin type and the interaction between light and pigment require individual assessment. Appropriate eye protection is essential. These considerations belong within the treating practitioner’s device-specific safety assessment.[8]

Clinical uses and the evidence behind them#

Observation and appearance-directed care

Recognised spider telangiectases are often harmless. Some settle spontaneously, while others persist; treatment is generally considered when appearance or bleeding troubles the person. Removal can leave a small scar, and lesions can recur.[2]

Facial vessels treated with vascular devices

Nymann and colleagues randomised 40 people with symmetrical facial telangiectases to split-face treatment using Vbeam 595-nm pulsed dye laser and Ellipse Flex IPL. Thirty-nine completed the study. Three months after the final treatment, the category of 75–100% vessel clearance was reached on 18/39 PDL-treated sides and 11/39 IPL-treated sides; the authors favoured PDL in this comparison. The retrieved original abstract does not provide the age distribution, phototypes or funding declaration.[4]

For rosacea-associated persistent facial erythema, the 2021 BAD guideline gives a weak recommendation to consider PDL, Nd:YAG or IPL and specifies an appropriately qualified laser practitioner. Several guideline authors disclosed industry relationships.[3]

A 2026 systematic review, whose searches ran to November–December 2023, extends the comparative evidence. Its telangiectasia network comprised five studies and 177 observations. Oxymetazoline plus PDL had a mean difference of −0.58 points, 95% CI −1.03 to −0.14, versus PDL on a harmonised 1–5 severity scale. Most studies had unclear or high risk of bias; the review supplied no formal GRADE or CINeMA certainty rating. The combination is evidence for clinician consideration in the studied rosacea context, not a prescribing instruction. The review was supported by the German Society for Dermatological Laser Medicine; two authors reported Cynosure Lutronic lecture fees.[5]

Selecting an assessment or treatment approach#

Begin with the pattern and purpose of care: a single stable spider lesion, diffuse redness with visible vessels, and widespread lesions with other symptoms lead to different discussions. Ask about onset, distribution, bleeding, relevant medicines and associated skin or general symptoms.[1][1, 6]i

When treatment is appropriate, the vessel’s morphology and location, skin type, likely recovery effects and the person’s priorities inform selection. A vascular specialist may consider different technologies for different presentations.[8]

Adverse effects and their management#

PDL can cause pain, redness, swelling and purpura — visible bruising from vascular effects. Blistering, pigment alteration and infection are recognised complications. Consent should address effects relevant to the selected procedure and skin type.[8]

Unexpected blistering, worsening pain or signs of infection warrant contact with the treating service and clinical assessment rather than further cosmetic treatment. The exact response depends on the injury.[8]

Referral and scope boundaries#

Bleeding and familial patterns:recurrent spontaneous nosebleeds, multiple vessels on the lips or inside the mouth, and a close relative with similar problems raise the possibility of hereditary haemorrhagic telangiectasia (HHT). Medical assessment matters because HHT can involve internal vascular malformations as well as visible vessels. The international guideline’s diagnostic recommendations G1–G2 were carried forward from the first guideline, with level III evidence and weak recommendation strength; recognition here is a reason to refer, not a diagnosis.[7, 9]i

Associated systemic features: new vascular changes alongside cold-triggered finger colour changes, thickened or tight skin, or swallowing symptoms merit GP assessment. These features can occur in systemic sclerosis.[1, 6]i

Lesions and ocular symptoms: uncertain individual lesions need diagnosis before cosmetic destruction. If rosacea includes eye symptoms, use the medical referral pathway described in rosacea, including prompt assessment of reduced vision or significant eye pain.[1, 8]i[3]

Mechanism of action#

Telangiectasia concerns vessel dilation, with the biological context differing between isolated lesions, inflammatory skin disease and inherited vascular disorders. In a spider lesion, a dilated central arteriole feeds the radiating vessels.[1][2]

Vascular PDL uses absorption by blood pigments to convert light energy into heat within the target. Preferential heating can damage the selected vessel; adjacent tissue can also be injured. This physical mechanism explains why vessel characteristics, skin type and device selection matter.[8]

Commonly misstated claims#

“Broken capillaries means the vessels have burst”

Claim heard: the visible lines are remnants of ruptured vessels.

Literature finding:the clinical definition is dilation. A spider lesion’s vessels can empty under pressure and refill, illustrating a continuing vascular connection.[1, 2]i

Supported statement:“Broken capillaries” is a familiar colloquial label; telangiectasia is visible widening of small vessels.

“Visible facial vessels mean rosacea”

Claim heard: facial telangiectasia is enough to diagnose rosacea.

Literature finding: rosacea is one context among several, including sun damage, familial patterns, medicine effects and other diseases. BAD guidance distinguishes its wider clinical features.[1, 3]i

Supported statement: Visible vessels contribute to an assessment; their cause depends on the surrounding signs and history.

“PDL always beats IPL for thread veins”

Claim heard: one favourable comparison establishes a universal technology ranking.

Literature finding: the Nymann trial explicitly concerned two specified pieces of equipment and a defined facial-vessel presentation. The subsequent rosacea network review combines a heterogeneous, often bias-prone evidence base.[4, 5]i

Supported statement: A comparison can favour the tested PDL device without proving that every PDL device is superior for every person or vessel pattern.

Areas of remaining uncertainty#

  • Durability and retreatment: long-term comparative data are limited. Discuss the possibility of recurrence and the uncertainty around future treatment needs.[2][5]
  • Skin-tone representation: many studies omitted phototype, and the 2026 review identified no reported phototype VI participants. Selection and consent need to acknowledge the limits of direct applicability.[5]
  • Comparative outcomes that matter to patients: trial measures and devices vary. Clearance scores, discomfort, recovery and satisfaction should be discussed separately when choosing between suitable options.[4, 5]i

Frequently asked questions#

Do all visible vessels need treatment?

No. Recognised, uncomplicated spider telangiectases can be observed when they do not trouble the person. The observation and referral sections explain the different pathways.[2]

Can someone have vessel treatment while receiving rosacea care?

Vascular treatment can form part of rosacea management. An appropriately qualified practitioner should coordinate the choice with the person’s clinical presentation and wider care.[3]

What information is useful at consultation?

Bring the history of when the vessels appeared, any bleeding or other symptoms, current medicines, previous treatment and the change you hope to achieve. These details help distinguish cosmetic concerns from patterns needing medical assessment.[1][1, 6]i[7, 9]i

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Oakley A. Telangiectasia. DermNet. 2014. Accessed 16 September 2026.Tier 4Supports: Definition, acquired and inherited contexts, medicine associations, vascular differential diagnosis and treatment overview.Funding / interest: Expert clinical reference; no article-specific funding or conflict statement located. The website carries advertising.
  2. Oakley A. Spider telangiectasis. DermNet. December 2017. Accessed 16 September 2026.Tier 4Supports: Central arteriole with radiating vessels, clinical recognition, spontaneous resolution or persistence, observation, treatment and recurrence.Funding / interest: Expert clinical reference; no article-specific funding or conflict statement located. The website carries advertising.
  3. Hampton PJ, Berth-Jones J, Duarte Williamson CE, et al. British Association of Dermatologists guidelines for the management of people with rosacea 2021. Br J Dermatol. 2021;185(4):725–735. doi:10.1111/bjd.20485.Tier 1Supports: R17 weak recommendation to consider PDL, Nd:YAG or IPL for persistent facial erythema in rosacea with an appropriately qualified laser practitioner; supportive care and ocular referral recommendations. Full publisher text retrieved.Funding / interest: Guideline reports no funding. Declared author relationships include PJH research or educational/travel support involving LEO, Janssen, UCB and Eli Lilly; CEDW speaker relationships with AbbVie, Galderma and Janssen; TAL advisory relationships with Galderma, La Roche-Posay and Novartis and Novartis speaking; DS Galderma conference travel. JBJ previously ran a rosacea clinical-trial unit.
  4. Nymann P, Hedelund L, Haedersdal M. Long-pulsed dye laser vs. intense pulsed light for the treatment of facial telangiectasias: a randomized controlled trial. J Eur Acad Dermatol Venereol. 2010;24(2):143–146. doi:10.1111/j.1468-3083.2009.03357.x. PMID:20205349.Tier 2Supports: Original abstract; single-blind split-face trial, 40 enrolled and 39 completing, three treatments per side, facial vessels assessed three months after final treatment. Vbeam 595-nm PDL versus Ellipse Flex IPL with specified applicators. Age distribution and phototypes unavailable in abstract.Funding / interest: Funding and conflicts unavailable in retrieved original abstract. Device manufacturers are identified, but this alone establishes neither sponsorship nor independence.
  5. Nguyen L, Sorbe C, Seeber N, Schneider SW, Herberger K. Laser and energy-based devices for treating rosacea – a systematic review and network meta-analysis. J Dtsch Dermatol Ges. 2026;24(1):24–32. doi:10.1111/ddg.15961. PMID:41273013.Tier 1Supports: Original full text and XML; 25 RCTs overall, literature search November 2023 and trial-register search December 2023. Telangiectasia network contained five studies and 177 observations, distinct from the review-wide 843 patients. Most studies had unclear or high risk of bias; no formal GRADE or CINeMA certainty rating reported.Funding / interest: Supported by the German Society for Dermatological Laser Medicine (DDL). Nguyen and Herberger disclosed lecture fees from Cynosure Lutronic; other authors declared no conflicts. Open-access funding through Projekt DEAL.
  6. NHS. Scleroderma. Reviewed 24 March 2023. Accessed 16 September 2026.Tier 4Supports: Raynaud symptoms, skin thickening, red spots and swallowing or reflux symptoms in systemic sclerosis. Public information rather than a formally developed clinical guideline.Funding / interest: NHS public information; no article-specific commercial funding identified.
  7. Faughnan ME, Mager JJ, Hetts SW, et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med. 2020. doi:10.7326/M20-1443.Tier 1Supports: Original guideline PDF; disease overview and table recommendations G1–G2. These diagnostic recommendations were carried forward from the first guidelines, not reassessed in 2020; original level III evidence and weak recommendation retained.Funding / interest: Christopher McMahon Family and Cure HHT supported the guidelines. Faughnan was supported by the Nelson Arthur Hyland Foundation and Li Ka Shing Knowledge Institute. The paper links separate author disclosure forms, which could not be retrieved; absence of commercial conflicts is not assumed.
  8. Ranaweera A. Pulsed dye laser treatment. DermNet. June 2014. Accessed 16 September 2026.Tier 4Supports: Vascular light absorption, treatment selection, diagnostic certainty, eye protection and recognised adverse effects. Device settings, historical regulatory descriptions and untraced adverse-event percentages are not used.Funding / interest: Expert clinical reference; no article-specific funding or conflict statement located. The website carries advertising.
  9. Ngan V. Hereditary haemorrhagic telangiectasia. DermNet. 2006. Accessed 16 September 2026.Tier 4Supports: Recognisable bleeding and mucocutaneous patterns and the four diagnostic-criteria domains. Used for recognition only, not current HHT drug treatment or prevalence figures.Funding / interest: Expert clinical reference; no article-specific funding or conflict statement located. The website carries advertising.